Patients should have insured access to interventional therapy for MGD AND Doctors should receive fair reimbursement for that therapy.

Unfortunately, that’s not the reality today- but Sight Sciences is investing in making this change happen.

Today only 5% of patients receive a thermal expression therapy,1 when 86% may need it.2

Sight Sciences and TearCare® are committed to changing this.


    Join the cause.









    I would like to be kept up to date on this topicI am interested in advocating for insured access and fair reimbursementI have experience submitting claims to payersI am active in a State/Regional organization

    Submit

    References

    1. Market Scope 2021 Ocular Surface Disease Survey.
    2. Lemp MA, et al. Cornea. 2012 May;31(5):472-478.

    Fair access footer information

    Skip to content